What is the difference between ARA-290 and MOTS-c?

ARA-290: Non-hematopoietic EPO analogue; activates innate repair receptor (IRR/EPOR/CD131 complex) without erythropoietic effects; promotes tissue repair and nerve healing MOTS-c: Mitochondria-derived peptide that translocates to nucleus under stress; activates AMPK pathway, regulates AICAR and folate-methionine cycle

Is ARA-290 FDA approved?

ARA-290 is investigational and not FDA approved. It is discussed for research and educational purposes only, not as medical guidance.

Is MOTS-c FDA approved?

MOTS-c is the subject of a favorable FDA advisory committee vote but not FDA approved, and its legal status for compounding is unchanged. It is discussed for research and educational purposes only, not as medical guidance.

How is ARA-290 administered in research settings?

In research settings, ARA-290 is typically administered via the subcutaneous or intravenous routes. PeptideBase does not provide dosing or administration instructions.

How is MOTS-c administered in research settings?

In research settings, MOTS-c is typically administered via the subcutaneous or intravenous routes. PeptideBase does not provide dosing or administration instructions.

Home›Research›Compare›ARA-290 vs MOTS-c

Peptide Comparison

ARA-290 vs MOTS-c

Name: ARA-290 vs MOTS-c — Per-mg Price Comparison
Creator: PeptideBase
License: https://peptidebase.io/terms

Both are Longevity & Cellular peptides.

ARA-290

Cibinetide

LongevityInvestigationalResearch Only

Half-life: ~2 min (IV); ~10–20 min (SC)

17 providers listed

Full ARA-290 profile →

MOTS-c

Mitochondrial ORF of the 12S rRNA type-c

LongevityAdvisory Vote: FavorableResearch Only

Half-life: Unknown (rapidly cleared from plasma)

185 providers listed

Full MOTS-c profile →

Bottom line

ARA-290 carries stronger published evidence (RCT, 2 key studies) than MOTS-c (Cohort study, 8); both are research compounds.

Quick Verdict

ARA-290

Half-life

~2 min (IV); ~10–20 min (SC)

MOTS-c

Half-life

Unknown (rapidly cleared from plasma)

Which One Should You Choose?

Your goal	Better option
Stronger clinical evidence	ARA-290
Further along in FDA review	ARA-290
More provider options (17 vs 185)	MOTS-c

Research summary only — not medical advice. Consult a qualified provider before making any decisions.

Side-by-Side Comparison

ARA-290

MOTS-c

Mechanism Family

Longevity & Cellular

Half-life

~2 min (IV); ~10–20 min (SC)

Unknown (rapidly cleared from plasma)

FDA Status

investigational

advisory committee recommended

Admin Routes

subcutaneous, intravenous

Availability

Research Only

Providers

17 listed

185 listed

FDA Update

—

Jul 2026

Avail. Notes

Non-hematopoietic EPO analog (cibinetide) by Araim Pharma. Phase 3 for sarcoidosis peripheral neuropathy; Dutch conditional marketing authorisation applied for. No FDA approval. Investigational.

Mitochondria-derived peptide encoded in 12S rRNA. Regulates metabolism and exercise capacity. No FDA approval, no NDA or IND. Pure research compound; no clinical development program.

Research Evidence

ARA-290

RCT · 2 key studies · most recent 2026

MOTS-c

Cohort study · 8 key studies · most recent 2026

Research Citations

ARA-290

RCT2017 · Investigative Ophthalmology & Visual Science

Cibinetide (ARA 290) reduces small nerve fiber pathology in sarcoidosis patients

Animal2026 · Neurobiol Dis

Immunometabolic dysregulation drives selective executive cognitive dysfunction in male db/db mice.

MOTS-c

Cohort2026 · J Clin Med

Reduced Circulating MOTS-c Levels in Hashimoto's Thyroiditis Reflect Integrated Autoimmune and Metabolic Dysr…

Animal2026 · Biomedicines

Humanin and MOTS-c Attenuate Atrial Fibrillation by Suppressing Fibrosis and Mitochondrial Dysfunction.

Animal2026 · Redox Biol

LAT1-mediated delivery of engineered R13A-MOTS-c attenuates radiation-induced lung injury via Nrf2 activation…

Animal2026 · Life Sci

MOTS-c attenuates hyperoxia-induced neonatal cardiac injury by inhibiting oxeiptosis via maintaining the KEAP…

+4 more

About ARA-290

Non-hematopoietic EPO analogue; activates innate repair receptor (IRR/EPOR/CD131 complex) without erythropoietic effects; promotes tissue repair and nerve healing

Research Areas

neuropathic pain relieftissue repairanti-inflammatorymetabolic improvement

About MOTS-c

Mitochondria-derived peptide that translocates to nucleus under stress; activates AMPK pathway, regulates AICAR and folate-methionine cycle

Research Areas

metabolic regulationinsulin sensitivityexercise mimicryanti-aging

Safety Profile

Information below reflects published research data only — not medical advice. Consult a qualified provider before use.

ARA-290

Reported (Unverified — Pending Clinical Review)

active erythrocytosis

No established clinical contraindications

MOTS-c

No established clinical contraindications. This is an investigational compound with limited human data and has not been evaluated by the FDA for safety in this context. Consult a qualified clinician.

Price (per mg)

ARA-290

$4.95/mg

$3.91 – $5.56 range

34 vendors

View price index →Find providers →

MOTS-c

$4.93/mg

$3.03 – $6.96 range

51 vendors

View price index →Find providers →

Find Providers

Where to source these peptides

Providers offering

ARA-290

17 listed

Browse directory →

Providers offering

MOTS-c

185 listed

Browse directory →

PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.

More Longevity & Cellular Comparisons

Browse all peptides →

Educational research tools — not medical advice.

Cite this page

Data last updated August 26, 2026

Free to reference and republish with attribution to PeptideBase. Choose a format:

PeptideBase. (2026). ARA-290 vs MOTS-c — Per-mg Price Comparison. Retrieved September 11, 2026, from https://peptidebase.io/peptides/compare/ara-290/mots-c

https://peptidebase.io/peptides/compare/ara-290/mots-c Methodology License Download JSON Download CSV